arrow
H

Heidi J. Gray

Thomas Jefferson University
H指数:41
被引数:9,470

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO

在一项关于 niraparib 联合 bevacizumab 维持治疗的研究中,该研究在晚期卵巢癌患者接受以 bevacizumab 辅助的一线铂类化疗后进行,报告了 OVARIO 研究的最终分析结果及总生存数据。

2025-07-010
OA
Ovarian Cancer/Fallopian Tube Cancer/Primary PeritonealCancer, Version 3.2024Featured Updates to the NCCN Guidelines

卵巢癌/输卵管癌/原发性腹膜癌,版本3.2024 NCCN指南重点更新

2024-10-0115
PRE
NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma

NRG/RTOG 0837: 在新诊断的胶质母细胞瘤中使用或不使用西地尼布进行放化疗的随机,II期,双盲,安慰剂对照试验

2023-10-116
OAAI
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing
2023-05-1816
OAAI
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
2021-03-178
OAAI
Ovarian Cancer, Version 2.2020
2021-02-01447
OA
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
2019-08-01211
OA
Ovarian Cancer, Version 1.2016
2016-09-01252
OAAI
Ovarian Cancer, Version 2.2013 Featured Updates to the NCCN Guidelines
2013-10-18127
OAAI
Ovarian Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines
2012-11-0883
OAAI